JP2017516775A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516775A5 JP2017516775A5 JP2016568918A JP2016568918A JP2017516775A5 JP 2017516775 A5 JP2017516775 A5 JP 2017516775A5 JP 2016568918 A JP2016568918 A JP 2016568918A JP 2016568918 A JP2016568918 A JP 2016568918A JP 2017516775 A5 JP2017516775 A5 JP 2017516775A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- treatment
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MKLKAQMPKHNQPR-NSHDSACASA-N C[C@@H](c(cc1)ccc1C(O)=O)NC(c(c(C(F)F)n[n]1C)c1Oc1cc(C(F)(F)F)ccc1)=O Chemical compound C[C@@H](c(cc1)ccc1C(O)=O)NC(c(c(C(F)F)n[n]1C)c1Oc1cc(C(F)(F)F)ccc1)=O MKLKAQMPKHNQPR-NSHDSACASA-N 0.000 description 4
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020096807A JP7562296B2 (ja) | 2014-05-23 | 2020-06-03 | がんの処置のための併用治療 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462002366P | 2014-05-23 | 2014-05-23 | |
| US62/002,366 | 2014-05-23 | ||
| US201562150004P | 2015-04-20 | 2015-04-20 | |
| US62/150,004 | 2015-04-20 | ||
| PCT/US2015/031931 WO2015179615A1 (en) | 2014-05-23 | 2015-05-21 | Combination therapies for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020096807A Division JP7562296B2 (ja) | 2014-05-23 | 2020-06-03 | がんの処置のための併用治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017516775A JP2017516775A (ja) | 2017-06-22 |
| JP2017516775A5 true JP2017516775A5 (oth) | 2018-06-28 |
| JP6787792B2 JP6787792B2 (ja) | 2020-11-18 |
Family
ID=53277114
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568918A Active JP6787792B2 (ja) | 2014-05-23 | 2015-05-21 | がんの処置のための併用治療 |
| JP2020096807A Active JP7562296B2 (ja) | 2014-05-23 | 2020-06-03 | がんの処置のための併用治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020096807A Active JP7562296B2 (ja) | 2014-05-23 | 2020-06-03 | がんの処置のための併用治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20170182003A1 (oth) |
| EP (2) | EP3134085B1 (oth) |
| JP (2) | JP6787792B2 (oth) |
| KR (1) | KR102535283B1 (oth) |
| CN (2) | CN110354266A (oth) |
| AU (1) | AU2015264102C1 (oth) |
| CA (1) | CA2949961C (oth) |
| IL (1) | IL249065A0 (oth) |
| MA (1) | MA39906A (oth) |
| MX (1) | MX393818B (oth) |
| RU (1) | RU2708374C2 (oth) |
| SG (1) | SG11201609770TA (oth) |
| WO (1) | WO2015179615A1 (oth) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102535283B1 (ko) | 2014-05-23 | 2023-05-22 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 암의 치료를 위한 조합 요법 |
| BR112018007664B1 (pt) | 2015-10-16 | 2023-12-19 | Eisai R&D Management Co., Ltd | Compostos antagonistas de ep4, composição compreendendo o composto e uso dos mesmos para tratar câncer |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| HUE057799T2 (hu) | 2016-07-07 | 2022-06-28 | Ono Pharmaceutical Co | EP4 antagonistát és immunellenõrzõpont gátlót tartalmazó kombináció |
| EP3505183B1 (en) | 2016-08-26 | 2022-03-30 | Tetsuji Okuno | Microvascular blood flow decreasing agent and use thereof |
| IL265921B2 (en) | 2016-10-14 | 2024-05-01 | Prec Biosciences Inc | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
| US10342785B2 (en) | 2016-11-04 | 2019-07-09 | Askat Inc. | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
| CN110621671A (zh) | 2017-05-18 | 2019-12-27 | 爱杜西亚药品有限公司 | 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物 |
| PL3625228T3 (pl) | 2017-05-18 | 2021-12-20 | Idorsia Pharmaceuticals Ltd | Pochodne pirymidyny jako modulatory receptora pge2 |
| EP3625224B1 (en) | 2017-05-18 | 2021-08-04 | Idorsia Pharmaceuticals Ltd | N-substituted indole derivatives |
| EA201992676A1 (ru) | 2017-05-18 | 2020-05-06 | Идорсия Фармасьютиклз Лтд | Фенильные производные в качестве модуляторов pge2 рецепторов |
| CN110621667A (zh) | 2017-05-18 | 2019-12-27 | 爱杜西亚药品有限公司 | 嘧啶衍生物 |
| CN108929281B (zh) * | 2017-05-27 | 2021-12-24 | 华东师范大学 | 三氮唑类化合物及其合成方法和应用 |
| JP7159007B2 (ja) * | 2017-11-01 | 2022-10-24 | 小野薬品工業株式会社 | 脳腫瘍の治療のための医薬 |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| US20200352906A1 (en) * | 2018-02-05 | 2020-11-12 | Shenzhen Ionova Life Science Co., Ltd. | Heterobicyclic Carboxylic Acids for Treating Cancer or Inflammatory Diseases |
| PL3759109T3 (pl) | 2018-02-26 | 2024-03-04 | Gilead Sciences, Inc. | Podstawione związki pirolizyny jako inhibitory replikacji hbv |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| US10973834B2 (en) * | 2018-04-16 | 2021-04-13 | Arrys Therapeutics, Inc. | EP4 inhibitors and use thereof |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| US20210315909A1 (en) | 2018-07-11 | 2021-10-14 | Arrys Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| WO2020081979A1 (en) * | 2018-10-19 | 2020-04-23 | Memorial Sloan-Kettering Cancer Center | Low dose radiation conditioning for immunotherapy |
| TW202136261A (zh) | 2018-10-31 | 2021-10-01 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| TWI721623B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| EP3889134B1 (en) * | 2019-01-22 | 2024-09-25 | Keythera (Suzhou) Pharmaceuticals Co. Ltd. | Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof |
| KR102707808B1 (ko) | 2019-03-07 | 2024-09-19 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭 |
| EP3935066A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| US20220233694A1 (en) * | 2019-05-31 | 2022-07-28 | The Cleveland Clinic Foundation | Functionalized fullerene gel tumor treatment |
| CN110386941A (zh) * | 2019-08-15 | 2019-10-29 | 上海邦耀生物科技有限公司 | Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗 |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CN119770638A (zh) | 2019-09-30 | 2025-04-08 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
| WO2021098750A1 (en) * | 2019-11-21 | 2021-05-27 | Beigene (Beijing) Co., Ltd. | Methods of cancer treatment with anti-ox40 antibody in comibinaiton with tlr agonists |
| US12410418B2 (en) | 2019-12-06 | 2025-09-09 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| KR102796877B1 (ko) * | 2020-03-04 | 2025-04-15 | 우한 휴먼웰 이노베이티브 드러그 리서치 앤드 디벨롭먼트 센터 리미티드 컴퍼니 | 신규 ep4 길항제의 합성 및 암과 염증에서의 이의 용도 |
| US11718637B2 (en) | 2020-03-20 | 2023-08-08 | Gilead Sciences, Inc. | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same |
| CN114075140A (zh) * | 2020-08-18 | 2022-02-22 | 武汉人福创新药物研发中心有限公司 | 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在癌症和炎症中的用途 |
| TWI877433B (zh) * | 2020-11-30 | 2025-03-21 | 大陸商杭州阿諾生物醫藥科技有限公司 | 用於治療ｐｉｋ３ｃａ突變癌症的組合療法 |
| US20240409516A1 (en) * | 2021-01-28 | 2024-12-12 | Shenzhen Zhongge Biological Technology Co., Ltd. | Pyrazolamide derivative, preparation method therefor, and application thereof |
| EP4337223A1 (en) | 2021-05-13 | 2024-03-20 | Gilead Sciences, Inc. | Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics |
| JP7673255B2 (ja) | 2021-06-11 | 2025-05-08 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ |
| TWI910028B (zh) | 2021-06-11 | 2025-12-21 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| TW202328073A (zh) * | 2021-09-03 | 2023-07-16 | 大陸商武漢人福創新藥物研發中心有限公司 | Ｅｐ４拮抗劑化合物及其鹽、多晶型及其製備方法和用途 |
| CN115364222A (zh) * | 2021-09-09 | 2022-11-22 | 首都医科大学附属北京地坛医院 | Ep4受体抑制剂治疗肝纤维化的应用 |
| US20250381143A1 (en) * | 2021-12-30 | 2025-12-18 | Adlai Nortye Biopharma Co., Ltd. | A solid pharmaceutical composition |
| WO2024027599A1 (zh) * | 2022-08-04 | 2024-02-08 | 杭州阿诺生物医药科技有限公司 | 预测直肠癌对an0025联合放疗/放化疗(rt/crt)治疗敏感性的生物标志物 |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| CN1889943A (zh) * | 2003-12-08 | 2007-01-03 | 美国亚利桑那大学董事会 | 协同抗癌组合物 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| EP2054401B1 (en) * | 2006-08-11 | 2013-05-01 | Merck Canada Inc. | Thiophenecarboxamide derivatives as ep4 receptor ligands |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| JP5411927B2 (ja) | 2008-05-06 | 2014-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ１アンタゴニストとしてのピラゾール化合物 |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| EP3431085B1 (en) * | 2009-04-22 | 2023-10-11 | AskAt Inc. | Selective ep4 receptor antagonistic substance for treatment of cancer |
| EP3375791A1 (en) | 2009-09-30 | 2018-09-19 | Memorial Sloan Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
| CA2806121C (en) | 2010-09-21 | 2018-10-09 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition |
| US20150004175A1 (en) * | 2011-12-13 | 2015-01-01 | Yale University | Compositions and Methods for Reducing CTL Exhaustion |
| KR102535283B1 (ko) * | 2014-05-23 | 2023-05-22 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 암의 치료를 위한 조합 요법 |
-
2015
- 2015-05-21 KR KR1020167035808A patent/KR102535283B1/ko active Active
- 2015-05-21 SG SG11201609770TA patent/SG11201609770TA/en unknown
- 2015-05-21 JP JP2016568918A patent/JP6787792B2/ja active Active
- 2015-05-21 CN CN201910572217.2A patent/CN110354266A/zh active Pending
- 2015-05-21 EP EP15726847.5A patent/EP3134085B1/en active Active
- 2015-05-21 WO PCT/US2015/031931 patent/WO2015179615A1/en not_active Ceased
- 2015-05-21 MX MX2016015363A patent/MX393818B/es unknown
- 2015-05-21 AU AU2015264102A patent/AU2015264102C1/en active Active
- 2015-05-21 CA CA2949961A patent/CA2949961C/en active Active
- 2015-05-21 CN CN201580039416.7A patent/CN106572993B/zh active Active
- 2015-05-21 MA MA039906A patent/MA39906A/fr unknown
- 2015-05-21 RU RU2016150650A patent/RU2708374C2/ru active
- 2015-05-21 EP EP25174070.0A patent/EP4656246A3/en active Pending
- 2015-05-21 US US15/312,980 patent/US20170182003A1/en not_active Abandoned
-
2016
- 2016-11-20 IL IL249065A patent/IL249065A0/en active IP Right Grant
-
2020
- 2020-06-03 JP JP2020096807A patent/JP7562296B2/ja active Active
-
2021
- 2021-11-17 US US17/528,510 patent/US11707448B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017516775A5 (oth) | ||
| JP2016533366A5 (oth) | ||
| RU2016150650A (ru) | Комбинированная терапия для лечения рака | |
| JP2017517506A5 (oth) | ||
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| BR112019024525A2 (pt) | composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c | |
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| CY1125326T1 (el) | Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων. | |
| JP2019532047A5 (oth) | ||
| MX419719B (es) | Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos. | |
| JP2019523214A5 (oth) | ||
| JP2018522858A5 (oth) | ||
| JP2017510661A5 (oth) | ||
| JP2015500225A5 (oth) | ||
| JP2016041733A5 (oth) | ||
| JP2016536286A5 (oth) | ||
| JP2018508512A5 (oth) | ||
| JP2016528162A5 (oth) | ||
| RU2019114963A (ru) | Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo | |
| JP2019533651A5 (oth) | ||
| MX385704B (es) | Derivado de heteroarilo o su sal farmacéuticamente aceptable, su método de preparación y composición farmacéutica para la prevención o tratamiento de enfermedades asociadas con pi3 cinasas que contiene el mismo como ingrediente activo. | |
| JP2016502515A5 (oth) | ||
| JP2015502926A5 (oth) | ||
| JP2016519107A5 (oth) | ||
| JP2019511550A5 (oth) |